Abstract：Objective To determine the expression of free carnitine and acylcarnitines in the sera of patients with polycystic ovary syndrome, and to explore their role in the pathogenesis of polycystic ovary syndrome. Methods Forty patients with polycystic ovary syndrome served as the experimental group and 29 healthy women as the control group. The expression of free carnitine and acylcarnitines in the serum samples from the two groups was determined and analyzed using NeoBaseTM Non-derivatized tandem mass spectrometry (MSMS) kit and MSMS system. Results No statistically significant difference was found in the expression of free carnitine between the two groups. The expression levels of 12 acylcarnitines such as methylcrotonoyl carnitine, glutaryl carnitine and adipoyl carnitine in the patients with polycystic ovary syndrome were all lower than those in the control group, with statistically significant differences (all P<0.05). But the expression of acetyl carnitine was significantly higher in the patients with polycystic ovary syndrome than in the controls (P<0.05). Conclusions There exists abnormal expression of carnitine in the sera of patients with polycystic ovary syndrome. The acetyl carnitine in the sera of patients with polycystic ovary syndrome is overexpressed. The abnormal expression of acylcarnitine may be involved in the pathogenesis and development of polycystic ovary syndrome; moreover, it is associated with insulin resistance and endocrine abnormality.
邹颖, 李红云, 曾梦君, 王映霞. 肉碱在多囊卵巢综合征患者中的表达及意义[J]. 实用预防医学, 2017, 24(8): 928-930.
ZOU Ying, LI Hong-yun, ZENG Meng-jun, WANG Ying-xia. Expression of carnitine in women with polycystic ovarian syndrome and its significance. , 2017, 24(8): 928-930.
[1] Goodarzi MO, Dumesic DA, Chazenbalk G, et al. Polycystic ovary syndrome:etiology, pathogenesis and diagnosis[J]. Nat Rev Endocrinol, 2011, 7(4):219-231. [2] Naderpoor N, Shorakae S, Joham A, et al. Obesity and polycystic ovary syndrome[J]. Minerva Endocrinol, 2015, 40(1):37-51. [3] Moran LJ, Misso ML, Wild RA, et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome:a systematic review and meta-analysis[J]. Hum Reprod Update, 2010, 16(4):347-363. [4] Atkin SL. Cardiovascular disease in polycystic ovary syndrome[J]. Clin Endocrinol (Oxf), 2013, 78(6):823-824. [5] Rizzo M, Berneis K, Spinas G, et al. Long-term consequences of polycystic ovary syndrome on cardiovascular risk[J]. Fertil Steril, 2009, 91(4 Suppl):1563-1567. [6] Targher G, Rossini M, Lonardo A. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance:a novel hepato-ovarian axis[J]. Endocrine, 2016, 51(2):211-221. [7] Vassilatou E. Nonalcoholic fatty liver disease and polycystic ovary syndrome[J]. World J Gastroenterol, 2014, 20(26):8351-8363. [8] Abdelkarem HM, Fadda LH, Hassan AA. Potential intervention of alpha-lipoic acid and carnitine on insulin sensitivity and anti-inflammatory cytokines levels in fructose-fed rats, a model of metabolic syndrome[J]. J Diet Suppl, 2016:1-11. [9] Tousson E, Hafez E, Zaki S, et al. The cardioprotective effects of L-carnitine on rat cardiac injury, apoptosis, and oxidative stress caused by amethopterin[J]. Environ Sci Pollut Res Int, 2016,23(10):20600-20608. [10] De Leo V, Musacchio MC, Cappelli V, et al. Genetic, hormonal and metabolic aspects of PCOS:an update[J]. Reprod Biol Endocrinol, 2016, 14(1):38. [11] Stephens FB, Constantin-Teodosiu D, Laithwaite D, et al. A threshold exists for the stimulatory effect of insulin on plasma L-carnitine clearance in humans[J]. Am J Physiol Endocrinol Metab, 2007, 292(2):E637-641. [12] Fenkci SM, Fenkci V, Oztekin O, et al. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome[J]. Hum Reprod, 2008, 23(7):1602-1606. [13] 沈树娜,芦胜群,王辉. 左旋肉碱在多囊卵巢综合征发病机制中的作用[J]. 中国计划生育学杂志,2013,21(9):611-613.
2017, Vol. 24 
